Liminal BioSciences Secures Interim Order For Proposed Arrangement With Structured Alpha LP
$LMNL
Biotechnology: Pharmaceutical Preparations
Health Care
Liminal BioSciences Secures Interim Order For Proposed Arrangement With Structured Alpha LP
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/24/2021 | Buy → Neutral | H.C. Wainwright |
LAVAL, QC and CAMBRIDGE, England, Sept. 26, 2023 /PRNewswire/ - Liminal BioSciences Inc. ("Liminal BioSciences" or the "Company") is pleased to announce that the transaction contemplated by the previously announced statutory plan of arrangement under the provisions of the Canada Business Corporations Act involving the Corporation and Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., was completed earlier today (the "Arrangement"). Pursuant to the Arrangement, SALP acquired all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates (the "Min
LAVAL, QC and CAMBRIDGE, England, Sept. 19, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price o
LAVAL, QC and CAMBRIDGE, England, Sept. 15, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that its shareholders have approved the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price of US$8.50 per Share, payable in cash (the "Arrangement"). Further
SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)
SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)
SC 13D/A - Liminal BioSciences Inc. (0001351172) (Subject)
H.C. Wainwright downgraded Liminal BioSciences from Buy to Neutral
Piper Sandler downgraded Liminal Biosciences from Overweight to Neutral and set a new price target of $4.50 from $22.00 previously
HC Wainwright initiated coverage of Liminal BioSciences with a rating of Buy and set a new price target of $11.00
LAVAL, QC, and CAMBRIDGE, England, March 13, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its fourth quarter and year ended 2022 financial results after market close on Wednesday March 15, 2023. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday March 16, 2023. To join the conference call without operator assistance, you may register and enter your phone number at https://bit.ly/3FeNJBk to receive an instant automated call back.
LAVAL, QC and CAMBRIDGE, England, Nov. 8, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today announced that it plans to report its third quarter 2022 financial results after market close on November 9, 2022. Liminal will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Thursday November 10, 2022. The telephone numbers to access the conference call are 888-205-6786 and 647-484-0474, using the following passcode: 722285. An audio replay of the call will be available as of Thursday November
$55.8M of cash and cash equivalents at June 30, 2022 Discontinuation of fezagepras developmentNet loss from continuing operations of $6.5 million during the quarter ended June 30, 2022 compared to $12.6 million during the quarter ended June 30, 2021LAVAL, QC and CAMBRIDGE, England , Aug. 9, 2022 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today reported its financial results for the second quarter ended June 30, 2022. Liminal BioSciences will host a conference call and webcast to discuss financial results at 8:30 am (ET) on Wednesday August 10, 2022. The telephone numbers to access the conference call are 888-390-0620 and 416-764-8651. An a
LAVAL, QC and CAMBRIDGE, England, June 5, 2023 /PRNewswire/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company") announced the voting results from its Annual General Meeting of Shareholders ("AGM") held virtually on June 5, 2023. A total of 2,235,519 common shares were voted, representing 72.02% of the votes attached to the issued and outstanding common shares of Liminal BioSciences. Election of Directors of the CompanyThe six (6) nominees set forth in the Circular were elected as directors of the Company to hold office until the next annual meeting of shareholders or until their successors are elected or appointed. Name of Nominee For Against Votes % Votes % Si
CTA-enabling work on track to seek approval to commence Phase 1 clinical trial of LMNL6511 during the second half of 2023Addition of GPR40 agonist discovery program aiming for the development of a novel liver-safe GPR40 agonist for the treatment of type 2 diabetes Closed December 31, 2022 with just over CAD 37 million cash on hand, expecting to provide cash runway into early 2024Net loss from continuing operations of CAD 6.6 million during the quarter ended December 31, 2022 compared to CAD 8.8 million during the fourth quarter of 2021Regained compliance with minimum bid price requirement for continued listing on the Nasdaq Capital MarketCompleted the sale of a non-core real estate asset at
$40.8M of cash and cash equivalents at September 30, 2022 Discontinuation of fezagepras developmentTermination of legacy CDMO agreement for cash savings of $33.1 millionNet loss from continuing operations of $4.5 million during the quarter ended September 30, 2022 compared to $9.7 million net loss for the same period 2021Current cash runway is anticipated to support our near-term development goals into the fourth quarter of fiscal 2023Possibilities to sell non-core assets to further extend runway into 2024Changes to strengthen executive leadership teamLAVAL, QC and CAMBRIDGE, England, Nov. 9, 2022 /CNW/ - Liminal BioSciences Inc. (NASDAQ:LMNL) ("Liminal BioSciences" or the "Company"), today
Liminal BioSciences Inc. (NASDAQ: LMNL) ("Liminal BioSciences" or the "Company"), is pleased to announce that it received the final order of the Ontario Superior Court of Justice (Commercial List) approving the previously-announced plan of arrangement under section 192 of the Canada Business Corporations Act (the "Arrangement") pursuant to which Structured Alpha LP ("SALP"), a limited partnership managed by its general partner, Thomvest Asset Management Ltd., will acquire all of the issued and outstanding common shares of Liminal BioSciences (the "Shares") not currently owned by SALP or its affiliates and associates at a price of US$8.50 per Share, payable in cash (the "Arrangement").
Second Quarter Ended June 30th 2023 Financial Results All figures presented in this section are in Canadian dollars. Cash and cash equivalents were $19.3 million at June 30, 2023 while our working capital, i.e., the current assets net of current liabilities, was $16.4 million. Research and development expenses were $4.3 million during the second quarter of 2023 compared to $3.9 million for the second quarter of 2022. The increase of $0.4 million in R&D expenses during the quarter ended June 30, 2023 compared to the corresponding period in 2022 was mainly attributable to an increase of $0.7 million in preclinical studies expense associated with the advancement of our GPR84 and OXER1 anta
15-12G - Liminal BioSciences Inc. (0001351172) (Filer)
EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)
EFFECT - Liminal BioSciences Inc. (0001351172) (Filer)